PL2504332T5 - Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej - Google Patents

Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej

Info

Publication number
PL2504332T5
PL2504332T5 PL10785289T PL10785289T PL2504332T5 PL 2504332 T5 PL2504332 T5 PL 2504332T5 PL 10785289 T PL10785289 T PL 10785289T PL 10785289 T PL10785289 T PL 10785289T PL 2504332 T5 PL2504332 T5 PL 2504332T5
Authority
PL
Poland
Prior art keywords
hemiartrate
genz
amorphous
inhibitor
crystalline form
Prior art date
Application number
PL10785289T
Other languages
English (en)
Polish (pl)
Other versions
PL2504332T3 (pl
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P. Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2504332(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL2504332T3 publication Critical patent/PL2504332T3/pl
Publication of PL2504332T5 publication Critical patent/PL2504332T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Molecular Biology (AREA)
PL10785289T 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej PL2504332T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
EP10785289.9A EP2504332B2 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
PCT/US2010/057952 WO2011066352A1 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Publications (2)

Publication Number Publication Date
PL2504332T3 PL2504332T3 (pl) 2014-10-31
PL2504332T5 true PL2504332T5 (pl) 2021-08-23

Family

ID=43431870

Family Applications (4)

Application Number Title Priority Date Filing Date
PL10785289T PL2504332T5 (pl) 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
PL19182732T PL3599237T3 (pl) 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
PL19182732T PL3599237T3 (pl) 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego

Country Status (40)

Country Link
US (6) US11458119B2 (enExample)
EP (5) EP2796457B1 (enExample)
JP (6) JP2013512252A (enExample)
KR (6) KR102073207B1 (enExample)
CN (5) CN112521367B (enExample)
AR (3) AR079152A1 (enExample)
AU (3) AU2010324810B2 (enExample)
BR (1) BR112012012947B8 (enExample)
CA (3) CA2781676C (enExample)
CL (2) CL2012001348A1 (enExample)
CR (1) CR20120277A (enExample)
CY (3) CY1115880T1 (enExample)
DK (3) DK2796457T3 (enExample)
DO (2) DOP2012000141A (enExample)
EA (3) EA023923B1 (enExample)
EC (2) ECSP12011926A (enExample)
ES (4) ES2754398T3 (enExample)
GT (1) GT201200161A (enExample)
HR (3) HRP20140780T4 (enExample)
HU (2) HUE029371T2 (enExample)
IL (4) IL310635A (enExample)
LT (2) LT3133070T (enExample)
MA (1) MA33838B1 (enExample)
ME (1) ME02477B (enExample)
MX (2) MX358345B (enExample)
MY (2) MY192644A (enExample)
NI (1) NI201200096A (enExample)
NZ (3) NZ625712A (enExample)
PE (2) PE20121337A1 (enExample)
PH (2) PH12012501048A1 (enExample)
PL (4) PL2504332T5 (enExample)
PT (4) PT2504332E (enExample)
RS (3) RS54978B1 (enExample)
SG (2) SG10201407881WA (enExample)
SI (3) SI2796457T1 (enExample)
SM (1) SMT201600273B (enExample)
TN (1) TN2012000237A1 (enExample)
TW (3) TWI656873B (enExample)
UA (1) UA113491C2 (enExample)
WO (1) WO2011066352A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
SI2753346T1 (sl) 2011-09-07 2020-09-30 Mount Sinai School Of Medicine Ceramidaza in diferenciacija celic
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
HUE051020T2 (hu) 2012-06-01 2021-01-28 Icahn School Med Mount Sinai A ceramid szintjei a fertõzések kezelésében és megelõzésében
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
US10227323B2 (en) * 2013-09-20 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
EP3164128A4 (en) * 2014-07-03 2018-02-28 Dr. Reddy's Laboratories Ltd. Amorphous form of eliglustat hemitartarate
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11116755B2 (en) 2015-11-18 2021-09-14 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
CA3014572C (en) 2016-02-25 2023-10-03 Asceneuron S.A. Acid addition salts of piperazine derivatives
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
TW201904577A (zh) 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
EP3664798B1 (en) * 2017-08-08 2025-10-29 Amneal Pharmaceuticals LLC Pharmaceutical composition comprising eliglustat
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
MX2020006272A (es) 2017-12-15 2020-09-14 Genzyme Corp Metodos para tratar la enfermedad de gaucher.
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
CN112512558A (zh) * 2018-05-27 2021-03-16 比奥阿赛斯技术有限公司 戈谢病的治疗
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
KR20240035456A (ko) * 2021-07-05 2024-03-15 페레르 인터내쇼날 에스.에이. 글리코시다제 저해제를 포함하는 의약
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
NZ269847A (en) 1993-08-13 1996-11-26 Seikagaku Kogyo Co Ltd 2-alkylamino-3-morpholino-1-propanol derivative in a composition for neuronal disease treatment
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
EP1008342A3 (en) 1994-02-02 2004-12-29 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
WO1995034530A1 (en) 1994-06-10 1995-12-21 Seikagaku Corporation 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
CA2336549A1 (en) 1998-07-27 2000-02-10 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
AU774960B2 (en) * 1999-07-09 2004-07-15 Regents Of The University Of Michigan, The Amino ceramide-like compounds and therapeutic methods of use
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
SK16372002A3 (sk) 2000-04-24 2003-04-01 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrát
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
HUP0401300A3 (en) 2001-01-18 2005-06-28 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
BR122015016313B8 (pt) 2001-07-16 2021-05-25 Genzyme Corp composto semelhante à ceramida e método de preparar um composto
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
DE60235632D1 (de) 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
EP2011489A3 (en) 2002-07-09 2009-04-22 Roberta Gottlieb Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
WO2005070938A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
CN101052383B (zh) 2004-09-17 2013-01-30 马萨诸塞大学 用于溶酶体酶缺乏症的组合物和其用途
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
BRPI0516001A (pt) 2004-10-13 2008-08-19 Pharmacia & Upjohn Co Llc formas cristalinas de 3-[5-cloro-4-[(2, 4-difluorobenzil) óxi]-6-oxopirimidin-1(6h)-il]-n-(2-hidroxietil)-4-metilben zamida
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
US20080293946A1 (en) * 2005-10-03 2008-11-27 Cheng Brian K Process for Preparing Zolpidem Hemitartrate and Tartrate Polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008089087A2 (en) * 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
US20100113517A1 (en) * 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2594562B1 (en) * 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
EP2227780A4 (en) 2008-03-19 2011-08-03 Existence Genetics Llc GENETIC ANALYSIS
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
RS59908B1 (sr) 2009-11-27 2020-03-31 Adverio Pharma Gmbh Postupak za proizvodnju metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata
RU2014101626A (ru) 2011-06-21 2015-07-27 Новартис Аг Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
KR20120115972A (ko) 2012-10-19
CN102712629A (zh) 2012-10-03
EP3896069A1 (en) 2021-10-20
JP2019001809A (ja) 2019-01-10
ME02477B (me) 2017-02-20
PT2796457T (pt) 2016-07-14
JP2020189873A (ja) 2020-11-26
SI2796457T1 (sl) 2016-10-28
HRP20161038T1 (hr) 2016-10-21
IL260299A (en) 2018-08-30
TW201737910A (zh) 2017-11-01
RS53503B2 (sr) 2021-07-30
HRP20191647T1 (hr) 2019-12-13
JP2016138124A (ja) 2016-08-04
NZ600155A (en) 2014-10-31
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
CL2012001348A1 (es) 2012-08-24
CY1122698T1 (el) 2021-03-12
ES2586947T3 (es) 2016-10-19
CN112521366A (zh) 2021-03-19
EP2504332B2 (en) 2021-03-17
EA201890254A2 (ru) 2018-10-31
HRP20140780T1 (en) 2014-11-07
BR112012012947B8 (pt) 2021-05-25
US11458119B2 (en) 2022-10-04
CN105753846B (zh) 2019-11-15
RS59543B1 (sr) 2019-12-31
PE20171255A1 (es) 2017-08-28
PT2504332E (pt) 2014-09-02
LT3133070T (lt) 2019-11-11
DK3133070T3 (da) 2019-11-11
IL219892A0 (en) 2012-07-31
NI201200096A (es) 2012-10-30
RS53503B1 (sr) 2015-02-27
JP6370264B2 (ja) 2018-08-08
KR20220162824A (ko) 2022-12-08
SG10201800136QA (en) 2018-02-27
TWI656873B (zh) 2019-04-21
PL3599237T3 (pl) 2021-09-27
AR079152A1 (es) 2011-12-28
AU2016202591B2 (en) 2017-11-30
LT2796457T (lt) 2016-09-12
CA2781676A1 (en) 2011-06-03
EP3133070B1 (en) 2019-08-14
EP3599237A1 (en) 2020-01-29
US20230172903A1 (en) 2023-06-08
EP2796457B1 (en) 2016-05-18
KR20250005503A (ko) 2025-01-09
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
HK1172031A1 (en) 2013-04-12
DK2796457T3 (en) 2016-08-29
HUE029371T2 (en) 2017-02-28
HRP20140780T4 (hr) 2021-08-06
TW201130822A (en) 2011-09-16
SI3133070T1 (sl) 2019-11-29
NZ715108A (en) 2017-06-30
EP3599237B1 (en) 2021-03-24
ES2493940T5 (es) 2021-11-23
TW201639562A (zh) 2016-11-16
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
SI2504332T2 (sl) 2021-08-31
PL2504332T3 (pl) 2014-10-31
CN112521367B (zh) 2024-01-02
JP2015212291A (ja) 2015-11-26
ES2754398T3 (es) 2020-04-17
ES2875382T3 (es) 2021-11-10
JP2013512252A (ja) 2013-04-11
CN102712629B (zh) 2016-10-12
US20210393590A1 (en) 2021-12-23
JP2023116764A (ja) 2023-08-22
SI2504332T1 (sl) 2014-09-30
BR112012012947B1 (pt) 2021-04-06
PT3133070T (pt) 2019-11-11
KR20180049255A (ko) 2018-05-10
KR20200013105A (ko) 2020-02-05
HK1203485A1 (en) 2015-10-30
EP2504332B1 (en) 2014-06-04
MA33838B1 (fr) 2012-12-03
CY1117996T1 (el) 2017-05-17
UA113491C2 (xx) 2017-02-10
DOP2012000141A (es) 2012-09-30
EP2796457A1 (en) 2014-10-29
PH12015502514A1 (en) 2016-08-15
JP6452635B2 (ja) 2019-01-16
EA201592195A1 (ru) 2016-04-29
US12465586B2 (en) 2025-11-11
TWI586663B (zh) 2017-06-11
JP7150528B2 (ja) 2022-10-11
HUE045784T2 (hu) 2020-01-28
EP3133070A1 (en) 2017-02-22
MY192644A (en) 2022-08-29
US10888547B2 (en) 2021-01-12
CL2016002589A1 (es) 2017-05-19
CN105777707B (zh) 2020-10-13
EA201890254A3 (ru) 2019-02-28
DK2504332T3 (da) 2014-08-25
EP2504332A1 (en) 2012-10-03
MX381242B (es) 2025-03-12
ECSP18063798A (es) 2020-02-28
US20160166542A1 (en) 2016-06-16
PL2796457T3 (pl) 2017-04-28
US20210369672A1 (en) 2021-12-02
ES2493940T3 (es) 2014-09-12
IL310635A (en) 2024-04-01
GT201200161A (es) 2014-01-27
CA3075788A1 (en) 2011-06-03
DOP2016000250A (es) 2017-02-15
CY1115880T1 (el) 2017-01-25
EA201270646A1 (ru) 2013-01-30
DK2504332T4 (da) 2021-06-07
AU2017265180B2 (en) 2019-08-01
WO2011066352A8 (en) 2011-08-11
US20160120842A1 (en) 2016-05-05
TN2012000237A1 (en) 2013-12-12
KR20150125734A (ko) 2015-11-09
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
CA3075788C (en) 2021-12-21
TWI606827B (zh) 2017-12-01
MY160542A (en) 2017-03-15
RS54978B1 (sr) 2016-11-30
PH12012501048A1 (en) 2013-02-04
PL3133070T3 (pl) 2020-01-31
AR121612A2 (es) 2022-06-22
BR112012012947A2 (pt) 2017-03-01
AU2016202591A1 (en) 2016-05-19
SG10201407881WA (en) 2015-01-29
ECSP12011926A (es) 2012-07-31
IL283935A (en) 2021-07-29
EA023923B1 (ru) 2016-07-29
EA029990B1 (ru) 2018-06-29
MX2012006083A (es) 2012-06-19
PT3599237T (pt) 2021-04-28
CA3140959A1 (en) 2011-06-03
AU2017265180A1 (en) 2017-12-14
CN112521367A (zh) 2021-03-19
US20130137743A1 (en) 2013-05-30
AU2010324810A1 (en) 2012-06-07
PH12015502514B1 (en) 2022-07-29
WO2011066352A1 (en) 2011-06-03
CA2781676C (en) 2020-05-05
CR20120277A (es) 2012-09-05
SMT201600273B (it) 2016-08-31

Similar Documents

Publication Publication Date Title
IL283935A (en) An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
CY2019014I1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
BRPI0911764A2 (pt) inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
HUE040355T2 (hu) Benzilbenzol SGLT2-inhibitor kristályformája
SMT201600291B (it) Inibitori di proteasi hcv
SMT201600275B (it) Composti eterociclici utili come inibitori di pdk1
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
EP2272817A4 (en) PAI-1 INHIBITORS
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
EP2477498A4 (en) INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
BR112012016178A2 (pt) inibidores de diacilglicerol aciltransferase
EP2413941A4 (en) Renin Inhibitors
EP2430016A4 (en) INV (LEUKEMIA) INHIBITORS
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
EP2483274A4 (en) ANTIMALARIA AGENTS AS AN INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE
EP2465524A4 (en) INHIBITOR FOR AUTOANTIKÖRPER MANUFACTURE
BRPI0910691A2 (pt) compostos e composições como inibidores de itpkb
EP2480076A4 (en) IMIDOTHIAZOLKINASEINHIBITOREN
EP2507219A4 (en) SYNTHESIS OF SYRBACTINE PROTEASOMMER
EP2467385A4 (en) Renin Inhibitors
IL225303A0 (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
AP2717A (en) Mono-hydrochloric salts of an inhibitor of histonedeacetylase
HRP20190034T1 (hr) Inhibicija biofilmskih organizama
TH0801000575A (th) บรรดาตัวยับยั้งของการออกฤทธิ์ Akt